Related coverage linked through entity extraction aliases.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 17, 2026
Novo Nordisk sues telehealth companies over compounded weight-loss drugs as employers explore AI-based alternatives to costly GLP-1 medications. About 1 in 8 Americans now take GLP-1 drugs for weight loss or diabetes.
Feb 20, 2026
Tirzepatide, the active ingredient in Mounjaro, reduced alcohol intake by more than half in animal models and prevented relapse-like drinking behaviors, offering potential insights for alcohol use disorder treatment.
Feb 18, 2026
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Feb 16, 2026
Scientists in China report reversing Type 2 diabetes in a patient using stem cell therapy, while a separate study finds metformin may help women with diabetes live past 90. Both findings require larger trials.
Feb 14, 2026
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
Feb 18, 2026
European regulators approved a 7.2mg "megadose" of Novo Nordisk's Wegovy involving three weekly injections. The Danish drugmaker filed suit against Hims & Hers after the telehealth company briefly launched a compounded oral semaglutide product.
Feb 17, 2026
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Feb 17, 2026
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
Feb 16, 2026
Researchers used a machine-learning tool to analyze 500,000 UK Biobank participants, providing the first population-scale evidence that insulin resistance is a risk factor for 12 types of cancer.
Feb 15, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and two additional collaborations totaling over $1 billion to develop treatments for immune disorders, cancer, and hearing loss gene therapies.
Feb 14, 2026
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
Feb 14, 2026
Novo Nordisk confronts rising generic threats to its semaglutide-based drugs while navigating FDA scrutiny and legal challenges. The company advances oral semaglutide into pediatric diabetes care as competitors prepare to launch imitations.
Feb 14, 2026
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
Feb 14, 2026
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Feb 13, 2026
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
Feb 14, 2026
Novo Nordisk launched oral Wegovy in January 2026 with strong early uptake, but faces FDA criticism over misleading advertising and legal battles over compounded alternatives as the company projects sales decline for 2026.
Feb 13, 2026
Viking Therapeutics reported a full-year 2025 net loss of $359.64 million as it rapidly advanced its obesity candidate VK2735 into Phase 3 trials, with both injectable and oral formulations showing double-digit weight loss in earlier studies.
